Effectiveness of the Digital Multimedia Health Education in Improving Cancer Pain, Analgesic Adherence, and Pain Control Satisfaction With Cancer Patient

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jan 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how effective digital multimedia health education can be in helping cancer patients manage their pain better. The researchers want to see if using engaging videos and graphics can help patients understand their pain, stick to their pain medication schedules, and feel more satisfied with their pain control. This is important because many cancer patients experience significant pain, but not all get the help they need to manage it.

To participate in this trial, you need to be an adult over 18 years old, diagnosed with a solid tumor, and reporting pain at a level of 4 or higher on a scale of 0 to 10. You should also be using strong prescribed pain medications and be able to communicate in Mandarin, either by speaking or writing. Participants can expect to learn about managing their pain and medications through digital tools that they can access on devices like smartphones or tablets, even when healthcare providers are busy. The goal is to empower patients to take control of their pain management and improve their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged over 18 years.
• • Diagnosed with a solid tumor and reporting a pain score of 4 or higher.
• • Patients using prescribed strong opioid medications for pain management.
• • Conscious, capable of communicating in Mandarin, understanding Mandarin, or -Able to write in text.
• • Able to operate electronic devices (e.g., smartphones, tablets, or computers) independently, or with assistance from family members or caregivers.
• Exclusion Criteria:
• • Patients with visual or auditory impairments.
• • Patients with cognitive impairments.
• • Diagnosed by a physician as having substance addiction (addictive substances include central nervous system depressants: opioids, heroin, ketamine; central nervous system stimulants: amphetamines, ecstasy, cocaine; and central nervous system hallucinogens: cannabis).